TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced further progress on Thursday in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. To date, 13 patients have received at ...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, ...
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that ...
No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results Several patients in the first and second cohort remain on ...
TransCode's TTX delivery platform is currently being evaluated in clinical trials, underscoring the translational feasibility of this immunotherapy approach. Molecular Imaging and Biology is a ...
TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injection TTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive ...
BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson ...
TransCode Therapeutics Inc (NASDAQ:RNAZ) shares are trading higher Thursday after the company announced it received written authorization from the FDA to proceed with its First-in-Human Phase 0 ...
BOSTON, April 27, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results